<sup>18</sup>F-FDOPA与<sup>18</sup>F-FDG PET/CT诊断脑肿瘤的系统评价

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (690 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the diagnostic value of ¹⁸F-FDOPA and ¹⁸F-FDG PET/CT scan in patients with brain tumors by Meta analysis.Methods Data on diagnostic experiments related to the diagnostic value of ¹⁸F-FDOPA and ¹⁸F-FDG PET/CT scan for brain tumors was retrieved from CNKI, CSJD, WanFang Database, CBM, PubMed, Embase, Cochrane Library by October 2016. The diagnostic value of ¹⁸F-FDOPA and ¹⁸F-FDG PET/CT scan for brain tumors was compared. Meta-DiSc 1.4 software was used to analyze the pooled sensitivity (SEN), specificity (SPE),positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR) under curve (AUC) the two different imaging agents.Results A total of four studies met the inclusion criteria. According to the results of 18F-FDOPA in diagnosis of brain tumors, the pooled SEN was 0.97(95%CI=0.90-1.00), SPE 0.67(95%CI=0.45-0.84),2.31(95%CI=1.40-3.81),0.07(95%CI=0.02-0.24), DOR 39.72(95%CI=8.94-176.48), SROC AUC 0.9725,and Q^* value. According to the diagnostic results of ¹⁸F-FD, the pooled SEN was 0.51(95%CI=0.39-0.63),0.75(95%CI=0.53-0.90),2.31(95%CI=0.70-3.61),0.07(95%CI=0.47-0.86),DOR 2.55(95%CI=0.82-7.92), SROC AUC 0.5848,and Q^* value was 0.5638.Conclusions ¹⁸F-FDOPA PET/CT imaging is more sensitive than ¹⁸F-FDG in the diagnosis of brain tumors.¹⁸F-FDOPA is of high diagnostic value for brain tumors and can be used as a reliable diagnostic method of brain tumors.

Key words： brain tumor PET/CT ¹⁸F-FDOPA ¹⁸F-FDG

Received: 13 December 2016

ZTFLH:	R817
	R739.41

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Shiming
	LUO Yanwei
	LI Yanfeng
	YANG Yang
	YUE Jianlan
	and LIN Zhichun

Cite this article:

HUANG Shiming,LUO Yanwei,LI Yanfeng等. A systematic comparison of ¹⁸F-FDOPA PET/CT with ¹⁸F-FDG PET/CT for diagnosis of brain tumors[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(6): 573-577.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I6/573

[1]	Ostrom Q T, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010[J]. Neuro Oncol, 2013, 15 (Sup 2):1-56.
[2]	Li Z, Yu Y, Zhang H, et al. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence[J]. Nucl Med Commun, 2015, 36(7):695-701.
[3]	李云,嵇辉,张燕齐,等. (18)F-FDG PET/CT显像寻找肿瘤原发灶25例[J]. 武警医学, 2012, 23(8):710-711.
[4]	Okochi Y, Nihashi T, Fujii M, et al. Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system[J]. Ann Nucl Med, 2014, 28(2):94-102.
[5]	Van Waarde A ,Elsinga P H. Proliferation markers for the differential diagnosis of tumor and inflammation[J]. Curr Pharm Des, 2008, 14(31):3326-3339.
[6]	Zhao C, Zhang Y, Wang J. A meta-analysis on the diagnostic performance of (18)F-FDG and (11)C-methionine PET for differentiating brain tumors[J]. AJNR Am J Neuroradiol, 2014, 35(6):1058-1065.
[7]	Calabria F,Cascini GL. Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence[J]. Hell J Nucl Med, 2014, 18(2):152-156.
[8]	Spence A M, Mankoff D A, Muzi M. Positron emission tomography imaging of brain tumors[J]. Neuroimaging Clin N Am, 2003, 13(4):717-739.
[9]	Glaudemans A W, Enting R H, Heesters M A, et al. Value of 11C-methionine PET in imaging brain tumours and metastases[J]. Eur J Nucl Med Mol Imaging, 2013, 40(4):615-635.
[10]	Minn H, Kauhanen S, Seppanen M, et al. 18F-FDOPA: a multiple-target molecule[J]. J Nucl Med, 2009, 50(12):1915-1918.
[11]	Whiting P, Rutjes A W, Reitsma J B, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews[J]. BMC Med Res Methodol, 2003, 3(1):25.
[12]	张俊,徐志伟,李克. 诊断性试验Meta分析的效应指标评价[J]. 中国循证医学杂志, 2013, 13(7):890-895.
[13]	Chen W, Silverman D H, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy[J]. J Nucl Med, 2006, 47(6):904-911.
[14]	Jora C, Mattakarottu J J, Aniruddha P G, et al. Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors - A pilot study[J]. Indian J Nucl Med, 2011, 26(2):78-81.
[15]	Karunanithi S, Sharma P, Kumar A, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2013, 40(7):1025-1035.
[16]	Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas[J]. Clin Nucl Med, 2009, 34(12):878-883.
[17]	Lawal I and Sathekge M. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection[J]. Br Med Bull, 2016, 120(1):55-74.
[18]	Struck A F, Hall L T, Kusmirek J E, et al. (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison[J]. Am J Nucl Med Mol Imaging, 2012, 2(4):475-482.
[19]	Scherfler C, Esterhammer R, Nocker M, et al. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease[J]. Brain, 2013, 136(10):3028-3037.
[20]	Oehme L, Perick M, Beuthien-Baumann B, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8):1550-1559.
[21]	Fueger B J, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas[J]. J Nucl Med, 2010, 51(10):1532-1538.
[22]	Pafundi D H, Laack N N, Youland R S, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study[J]. Neuro-oncology, 2013, 15(8):1058-1067.
[23]	Becherer A, Karanikas G, Szabó M, et al. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine[J]. Eur JNucl Med Mol Imaging, 2003,30(11):1561-1567.